In the Claims:

This listing of the claims will replace all prior versions and listing of the claims in the instant application.

- 1. (Original) An isolated polynucleotide comprising a nucleic acid sequence at least 95% identical to a polynucleotide which encodes a polypeptide selected from the group consisting of:
- (a) a N-terminal deletion fragment described by the general formula m-396 of SEQ ID NO:2;
- (b) a C-terminal deletion fragment described by the general formula -23-n of SEQ ID NO:2;
- (c) a N-terminal and C-terminal deletion fragment described by the general formula m-n of SEQ ID NO:2; and
- (d) a C-terminal deletion fragment described by the general formula +9-n of SEQ ID NO:2.
- 2. (Original) The isolated polynucleotide of claim 1, wherein said polypeptide comprises amino acid residues S-205 to S-396 of SEQ ID NO:2 and/or amino acid residues F-9 to R-203 of SEQ ID NO:2.
 - 3. (Original) A composition comprising the isolated polynucleotide of claim 1.
- 4. (Original) The isolated polynucleotide of claim 1, wherein the polynucleotide encodes a biologically active fragment of VEGF-2.
- 5. (Original) The isolated polynucleotide of claim 1, wherein the polynucleotide encodes a polypeptide which binds an antibody for VEGF-2.
- 6. (Original) The polynucleotide of claim 1 further comprising a polynucleotide which encodes a heterologous polypeptide.
 - 7. (Original) A vector comprising the polynucleotide of claim 1.

- 8. (Original) The vector of claim 7, wherein said polynucleotide is operatively associated with a heterologous regulatory sequence.
- 9. (Currently Amended) A host cell comprising the vector of claim 7 or the polynucleotide of claim 1.
 - 10. (Original) A method for producing a VEGF-2 polypeptide, comprising:
- (a) culturing the host cell of claim 9 under conditions suitable to produce the polypeptide; and
 - (b) recovering the polypeptide from the cell culture.
 - 11. (Original) The polypeptide produced by the method of claim 10.
- 12. (Original) An isolated polypeptide comprising polypeptide at least 95% identical to an amino acid sequence selected from the group consisting of:
- (a) a N-terminal deletion fragment described by the general formula m-396 of SEQ ID NO:2;

3

- (b) a C-terminal deletion fragment described by the general formula -23-n of SEQ ID NO:2;
- (c) a N-terminal and C-terminal deletion fragment described by the general formula m-n of SEQ ID NO:2; and
- (d) a C-terminal deletion fragment described by the general formula +9-n of SEQ ID NO:2.
- 13. (Original) The isolated polypeptide of claim 12, wherein said polypeptide comprises amino acid residues S-205 to S-396 of SEQ ID NO:2 and/or amino acid residues F-9 to R-203 of SEQ ID NO:2.
 - 14. (Original) A composition comprising the isolated polypeptide of claim 1.

- 15. (Original) A composition comprising a first polypeptide fragment comprising amino acids residues S-205 to S-396 of SEQ ID NO:2 and a second polypeptide fragment comprising amino acid residues F-9 to R-203 of SEQ ID NO:2.
- 16. (Original) The isolated polypeptide of claim 12, wherein the polypeptide is a biologically active fragment.
- 17. (Original) The isolated polypeptide of claim 12, wherein the polypeptide is antigenic.
- 18. (Original) The isolated polypeptide of claim 12, further comprising a heterologous polypeptide.
 - 19. (Original) An antibody to the polypeptide of claim 12.
 - 20. (Original) A compound which activates the polypeptide of claim 12.
 - 21. (Original) A compound which inhibits the polypeptide of claim 12.
- 22. (Currently Amended) A method for preventing, treating, or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of the polypeptide of claims 12-13, the composition of claims 3, 14-15, or of the polynucleotide of claim 1-12 claim 12.
- 23. (Original) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising:
- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1;
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

3

Docket No.: PF112P3C2US

- 24. (Original) A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject related to expression or activity of a secreted protein comprising:
- (a) determining the presence or amount of expression of the polypeptide of claim 12 in a biological sample;
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
- 25. (Currently Amended) A method for identifying binding partner to the polypeptide of elaim 10 claim 12 comprising:
 - (a) contacting the polypeptide of claim 12 with a binding partner; and
 - (b) determining whether the binding partner effects an activity of the polypeptide.
- 26. (Original) A method of identifying an activity in a biological assay, wherein the method comprises:
 - (a) expressing the polypeptide of claim 12 in a cell;
 - (b) isolating the supernatant;
 - (c) detecting an activity in a biological assay; and
 - (d) identifying the protein in the supernatant having the activity.
- 27. (New) A method for preventing, treating, or ameliorating a medical condition which comprises administering to a mammalian subject the composition of claim 3.
- 28. (New) A method for preventing, treating, or ameliorating a medical condition which comprises administering to a mammalian subject the polynucleotide of claim 1.
 - 29. (New) A host cell comprising the polynucleotide of claim 1.